[1] TORRE L A,BRAY F,SIEGEL R L,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[2] YU S H,WANG T H,AU L C.Specific repression of mutant K-RAS by 10-23 DNAzyme:sensitizing cancer cell to anti-cancer therapies[J].Biochem Biophys Res Commun,2009,378(2):230-234.
[3] TAN C,DU X.KRAS mutation testing in metastatic colorectal cancer[J].World J Gastroenterol,2012,18(37):5171.
[4] YOKOTA T.Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?[J].Anticancer Agents Med Chem,2012,12:163-171.
[5] DOMAGAL/A P,HYBIAK J,SULZ·YC-BIELICKA V,et al.Kras mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy:a practical approach[J].Pol J Pathol,2012,63:145-164.
[6] SPANO J P,FAGARD R,SORIA J C,et al.Epidermal growth factor receptor signaling in colorectal cancer:preclinical data and therapeutic perspectives[J].Ann Oncol,2005,16(2):189-194.
[7] CHANG F,STEELMAN L S,LEE J T,et al.Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors:potential targeting for therapeutic intervention[J].Leukemia,2003,17(7):1263-1293.
[8] MARTINELLI E,de PALMA R,ORDITURA M,et al.Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy[J].Clin Exp Immunol,2009,158(1):1-9.
[9] TABERNERO J,van CUTSEM E,DÍAZ-RUBIO E,et al.Phase Ⅱ trial of cetuximab in combination with fluorouracil,leucovorin,and oxaliplatin in the first-line treatment of metastatic colorectal cancer[J].J Clin Oncol,2007,25(33):5225-5232.
[10] van CUTSEM E,PEETERS M,SIENA S,et al.Open-label phase Ⅲ trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer[J].J Clin Oncol,2007,25(13):1658-1664.
[11] JONKER D J,O'CALLAGHAN C J,KARAPETIS C S,et al.Cetuximab for the treatment of colorectal cancer[J].N Engl J Med,2007,357(20):2040-2048.
[12] LIEVRE A,BACHET J B,le CORRE D,et al.KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer[J].Cancer Res,2006,66(8):3992-3995.
[13] KHAMBATA-FORD S,GARRETT C R,MEROPOL N J,et al.Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab[J].J Clin Oncol,2007,25(22):3230-3237.
[14] de ROOCK W,PIESSEVAUX H,de SCHUTTER J,et al.KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab[J].Ann Oncol,2008,19(3):508-515.
[15] LIÈVRE A,BACHET J B,BOIGE V,et al.KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab[J].J Clin Oncol,2008,26(3):374-379.
[16] BIBEAU F,LOPEZ-CRAPEZ E,di FIORE F,et al.Impact of FcγRⅡa-FcγRⅢa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan[J].J Clin Oncol,2009,27(7):1122-1129.
[17] DAHABREH I J,TERASAWA T,CASTALDI P J,et al.Systematic review:Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer[J].Ann Intern Med,2011,154(1):37-49.
[18] HEINEMANN V,von WEIKERSTHAL L F,DECKER T,et al.FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3):a randomised,open-label,phase 3 trial[J].Lancet Oncol,2014,15(10):1065-1075.
[19] THERKILDSEN C,BERGMANN T K,HENRICHSEN-SCHNACK T,et al.The predictive value of KRAS,NRAS,BRAF,PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer:a systematic review and meta-analysis[J].Acta Oncologica,2014,53(7):852-864.
[20] SOEDA H,SHIMODAIRA H,WATANABE M,et al.Clinical usefulness of KRAS,BRAF,and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan-and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer[J].Int J Clin Oncol,2013,18(4):670-677.
[21] SORICH M J,WIESE M D,ROWLAND A,et al.Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer:a meta-analysis of randomized,controlled trials[J].Ann Oncol,2015,26(1):13-21.
[22] DOUILLARD J Y,OLINER K S,SIENA S,et al.Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer[J].New Engl J Med,2013,369(11):1023-1034.
[23] AL-SHAMSI H O,ALHAZZANI W,WOLFF R A.Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers[J].J Gastrointest Oncol,2015,6(3):314.
[24] ANDREYEV H J N,NORMAN A R,CLARKE P A,et al.Kirsten ras mutations in patients with colorectal cancer:the multicenter "RASCAL" study[J].J Natl Cancer Inst,1998,90(9):675-684.
[25] ANDREYEV H J N,NORMAN A R,CUNNINGHAM D,et al.Kirsten ras mutations in patients with colorectal cancer:the 'RASCAL Ⅱ'study[J].Br J Cancer,2001,85(5):692.
[26] SAMOWITZ W S,CURTIN K,SCHAFFER D,et al.Relationship of Ki-ras mutations in colon cancers to tumor location,stage,and survival:a population-based study[J].Cancer Epidemiol Biomarkers Prev,2000,9(11):1193-1197.
[27] CONLIN A,SMITH G,CAREY F A,et al.The prognostic significance of K-ras,p53,and APC mutations in colorectal carcinoma[J].Gut,2005,54(9):1283-1286.
[28] KARAPETIS C S,KHAMBATA-FORD S,JONKER D J,et al.K-ras mutations and benefit from cetuximab in advanced colorectal cancer[J].N Engl J Med,2008,359(17):1757-1765.
[29] van KRIEKEN J,JUNG A,KIRCHNER T,et al.KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma:proposal for an European quality assurance program[J].Virchows Archiv,2008,453(5):417-431.
[30] MOLINARI F,FELICIONI L,BUSCARINO M,et al.Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer[J].Clin Cancer Res,2011,17(14):4901-4914.
[31] ANDERSON S M.Laboratory methods for KRAS mutation analysis[J].Expert Rev Mol Diagn,2011,11(6):635-642, 631.
[32] WHITEHALL V,TRAN K,UMAPATHY A,et al.A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting[J].J Mol Diagn,2009,11(6):543-552. |
